Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum
Conditions:   HIV Infections;   Tuberculosis Interventions:   Drug: Bictegravir (BIC);   Drug: Tenofovir alafenamide (TAF);   Drug: Cabotegravir (CAB);   Drug: Dolutegravir (DTG);   Drug: Atazanavir/ritonavir (ATV/r);   Drug: Darunavir/ritonavir (DRV/r);   Drug: Lopinavir/ritonavir (LPV/r);   Drug: Cobicistat;   Drug: Ritonavir;   Drug: First-Line TB Treatment;   Drug: Second-Line TB Treatment;   Drug: Doravirine (DOR) Sponsor...
Source: ClinicalTrials.gov - August 19, 2020 Category: Research Source Type: clinical trials

A Study of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Evaluated as a Fixed Dose Combination Regimen in Participants Switching From an Integrase Inhibitor Who Have Experienced Rapid Weight Gain
Condition:   HIV-1 Interventions:   Drug: D/C/F/TAF FDC;   Drug: TAF/FTC FDC;   Drug: INI Based Regimen Sponsor:   Janssen Scientific Affairs, LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 23, 2020 Category: Research Source Type: clinical trials

Darunavir/Cobicistat vs. Lopinavir/Ritonavir in COVID-19 Pneumonia in Qatar
Conditions:   Coronavirus;   COVID;   Pneumonia Interventions:   Drug: Darunavir/Cobicistat;   Drug: Lopinavir/Ritonavir Sponsor:   Hamad Medical Corporation Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 12, 2020 Category: Research Source Type: clinical trials

Rapid Reinitiation of a Single Tablet Antiretroviral Therapy Using Symtuza ® in HIV-1 Infected Treatment-Experienced Patients Off Therapy. (ReSTART)
Condition:   HIV-1-infection Intervention:   Drug: Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (FDC) Sponsors:   The Crofoot Research Center, Inc.;   Janssen Scientific Affairs, LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 14, 2020 Category: Research Source Type: clinical trials

Bioequivalence Study of GP30101 800 mg (GEROPHARM) Versus PREZISTA ® 800 mg ( " Jonson & Jonson " , Russia)
Condition:   Bioequivalence Interventions:   Drug: GP30101;   Drug: Prezista® Sponsor:   Geropharm Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 13, 2020 Category: Research Source Type: clinical trials